Half Year 2025 Herantis Pharma Oyj Earnings Call Transcript
Key Points
- HER-096, Herantis Pharma PLC's lead asset, shows potential as a game-changing therapy for Parkinson's disease by modifying the disease rather than just treating symptoms.
- The company has demonstrated strong preclinical data showing HER-096's ability to protect dopamine neurons and support their functional restoration.
- Herantis Pharma PLC has completed the Phase 1b clinical trial and is preparing for a Phase 2 proof of concept clinical trial, with top-line data expected by mid-October.
- The company has secured significant funding, including EUR5.2 million from a directed share issue and support from the Michael J. Fox Foundation and Parkinson UK.
- HER-096 offers a patient-friendly subcutaneous administration with a promising safety profile, enhancing its potential for commercial success.
- Herantis Pharma PLC reported an increased loss of EUR3.2 million compared to EUR2.6 million in the same period last year, primarily due to increased payroll and related expenses.
- The company requires additional funding to start the Phase 2 clinical trial, as the current cash runway only extends into Q2 2026.
- The Phase 1b data analysis process is lengthy, taking 6 to 9 weeks to report top-line data, which may delay further development stages.
- The final design of the Phase 2 study cannot be completed until Phase 1b data is fully analyzed, potentially delaying the trial's commencement.
- Herantis Pharma PLC's future funding plans are uncertain, relying on potential partnerships, scientific collaborations, and additional equity raises.
Good morning and welcome to Herantis Farmers' first half '25 webinar. I am the CEO, Antti Vuolanto. With me, I have here CFO, Tone Kvåle. Before going into the webinar presentation just a disclaimer about the forward-looking statements, I won't read them through, but let's continue with the presentation. So Herantis Pharma, we are a clinical stage public company listed at Helsinki, First North, and we develop neuro regenerative therapies to stop Parkinson's disease progression.
And our lead asset can actually become a game changing therapy as the first disease modifying treatment for Parkinson's disease. HER-096 is a small peptide that mimics the CDNF protein that the company has studied earlier.
And with the mechanism of action coming from [CDNF] protein, HER-096 can protect dopamine neurons from further degeneration and also support their functional restoration. And in addition to that, with the peptide, we have efficient brain penetration that enables, patient-friendly administration under the skin. We have very
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
